VantAI

VantAI is at the forefront of artificial intelligence (AI) research, aiming to “program” protein interactions. Specializing in computational biology and machine learning, VantAI combines these methods with structural proteomics and proximity modulators to accelerate the discovery of new medicines. This proximity modulation method has extensive applications in various diseases through targeting pathways like protein degradation. Mapping these protein interactions will help identify novel therapeutic targets. Through the integration of AI-driven methodologies, VantAI seeks to revolutionize pharmaceutical research, offering promising solutions to complex healthcare challenges. VantAI also collaborates with industry leaders such as Janssen and Bristol Myers Squibb.